ABC and GCB subtype sinonasal DLBCL are geno- and phenotypically distinct entities, exhibiting a contrasting disease course and prognosis. ow.ly/lFOO50Rmt9n #lymphoidneoplasia

An exciting opportunity to work with me, Martin Pule and Claire Roddie on developing novel cellular therapies for Myeloproliferative Neoplasms.

Apply on the link 👇

ucl.ac.uk/work-at-ucl/se…

Grateful to Blood Cancer UK Research and Medical Research Council for their ongoing support of our research.

#ESHLYMPHOMA2024 Submit your abstract & register for the conference in Stockholm 🇸🇪 on November 1-3, 2024!
Proceed here ➡ bit.ly/3NDQ8Lq
4th How to Diagnose and Treat #LYMPHOMA
Chairs: Christian Buske, Michael Crump, Gilles Salles, C. Thieblemont
#ESHCONFERENCES #Lymsm

🔎 How can you find reliable information online on #CART treatment?

T2EVOLVE has developed a video explaining how to do so in 3 steps together with the Working Group of Patients and Caregivers, Acute Leukemia Advocates Network (ALAN), Lymphoma Coalition & Myeloma Patients Europe.

Find it here: t2evolve.fyi/CART_info_video

From IPI and Lugano criteria to AI models brilliant overview on the role of PET radiomics in DLBCL and CAR-T. ⁦⁦Jurgen Kuball⁩ ⁦MarieJosé Kersten⁩

Excited to experiment with these! 😎🎨

Locke et al (MarieJosé Kersten) PET sub-analysis of ZUMA-7 out in Blood Journal
#lymSM
Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume ashpublications.org/blood/article/…

📣 We are pleased to announce the 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients #ESHCART2025
SAVE THE DATE: September 26-28, 2025 in Stockholm 🇸🇪
Chairs: Ulrich Jäger, MarieJosé Kersten, Loretta J. Nastoupil, MD
➡️ bit.ly/3TExODA
#ESHCONFERENCES #HAEMATOLOGY

Putting all co-authors email addresses and institutions individualy during the paper submission while everything is already on the paper is such a waste of time (doesn't matter who is doing it) and has to stop. Submitting a manuscript should not be so ridiculously complicated and…

Thoughtful editorial by Dr. Radford on newly appreciated Doxorubicin and Breast Cancer Risk, emphasizing importance of Long-Term Follow-Up in Curable Cancers Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

🗨️ What meaningful quality of life & self-reported health status questions should be asked routinely?

➡️ A #Tandem24 session on the topic with MarieJosé Kersten of Amsterdam UMC, Cancer Center Amsterdam - Amsterdam UMC & Mahmoud Elsawy, MD, MSc, DRCPSC, of Dalhousie University starts at 12:30 p.m. CT.

Doxorubicin Exposure and Breast Cancer Risk: These results emphasize the importance of very long follow-up for survivors of HL, and, if validated in other datasets, provide another factor to consider when evaluating risks of therapy. Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…

Our lab is hiring! Looking for a mixed dry-wet lab or computational postdoc to investigate biomarkers of treatment response and resistance in B-cell #lymphomas using bulk and single cell multiomics. Please RT. Reach out if interested in the role
jobs.ac.uk/job/DGB780/pos…

We are hiring! Vacany for research technician. 🔬🔬🔬Experience with flow cytometry is a plus! The Netherlands Cancer Institute nki.nl/careers-study/…

Thank you all for joining us at our Annual Consortium Meeting in Valencia!

We look forward to the next opportunity to connect and learn from the different work packages.

Find more photos and info about T2EVOLVE here: t2evolve.com/thank-you-for-…

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
nature.com/articles/s4137…
#MDSsm #EPO #SF3B1 #lymphocyte Leukemia Journal AA&MDSIF International Consortium for MDS (icMDS)

Me and all the papers I’ve downloaded but never read

European myeloma patients and caregivers, we want your input!

Join us in exploring preferences for myeloma treatment administration. The survey is open across Europe in multiple languages, including English, Polish, Norwegian, French, Dutch and German.
mpe.getfeedback.com/treatmentsurvey